Bruce Halpryn Application PackageHalpryn Bruce M
Last Name First Name Middle Initial
1455 Ocean Drive, #1509 Miami Beach
Home Address City
Florida 33139
State Zip Code
+1 513-659-4690+1 513-659-4690
HomeWork
bmh3557@hotmail.com
Email Address
+1 513-659-4690
Cellular
Miami Beach
Business Address
2160 Park Ave, Suite 100
City
Florida
State
33139
Zip Code
VISU Contemporary, LLC
Occupation:Business Name:
CEO
Please list your preferences in order of ranking [1] first choice [2] second choice, and [3] third choice. Please note
that only three (3) choices will be observed by the City Clerk’s Office. (Regular Boards of City)
Choice 1:
Choice 2:
Choice 3:
General Obligation (G.O.) Bond Oversight Committee
BOARD AND COMMITTEE
APPLICATION FORM
Note:If applying for the At-Large position of the Historic Preservation Board, please answer the below
questions:
Have you ever resided in one of the City's Historic Districts for at least one year?Yes
No Address in City Historic District submitted.
Professional License
No Professional Licenses Submitted.
Note:If you are seeking appointment to a professional seat (e.g. attorney, architect, etc.), you must attach a copy of
your currently effective corresponding professional license.
Pursuant to City Code section 2-22(4) a, b and c: Members of Agencies, Boards, and Committees shall be
affiliated with the city. This requirement shall be fulfilled in the following ways:
YesResident of the City for a minimum of six (6) months:
Demonstrate an ownership interest in a business established in the City for a minimum of six (6) months:Yes
AFFILIATION WITH THE CITY OF MIAMI BEACH
a.
● I am resident of:South Beach
Or
b.
"Ownership Interest" shall mean the ownership of ten percent (10%) or more (including the ownership of 10%
or more of the outstanding capital stock) in a business.
"Business" shall mean any sole proprietorship, sponsorship, corporation, limited liability company, or other
entity or business association.
c.Full-time employee of such a business (for a minimum of six months); and I am based in an office or
other location of the business that is physically located in Miami Beach (for a minimum of six months):No
Notwithstanding the requirements set forth herein, the qualified full-time employee of a business must be
approved by a 4/7th vote of the Mayor and City Commission.
NOTE: Members of Agencies, Boards, and Committees shall be required to demonstrate compliance with the
City affiliation requirements of section 2-22 (4) a and b of the Miami Beach City Code by executing an affidavit,
stipulating that they have met either (or both) of said affiliation requirements. The original affidavit shall be filled
with the Office of the City Clerk prior to being sworn in as a member.
Or
No● Have you ever been convicted of a felony:If yes, please explain in detail:
● Do you currently have a violation(s) of City of Miami Beach codes:No If yes, please explain in detail:
● Do you currently owe the City of Miami Beach any money:No If yes, please explain in detail:
● Are you currently serving on any City Boards or Committees:No If yes, which board?
● Are you presently a registered lobbyist with the City of Miami Beach?No
● I am applying for an appointment because I have special abilities, knowledge and experience. Please list below:
I am a serial entrepreneur, and am currently CEO of my fourth pharmaceutical development company,
Eikonoklastes Therapeutics, Inc. which provides me with a strong financial and business background. I am also
majority owner and co-curator of VISU Contemporary, LLC, a fine-art gallery in Miami Beach. I currently serve on
the board of directors of Miami City Ballet, where I sit on the finance committee, the personnel and compensation
committee, and chair the school committee. I also serve on the board of directors of FotoFocus, the largest
photography and lens-based art biannual in the USA where I was president of the board for 8 years and having
termed-out as president, I currently serve t
NOTE: IF APPOINTED, YOU WILL BE REQUIRED TO FOLLOW CERTAIN LAWS THAT APPLY TO CITY
BOARD/COMMITTEE MEMBERS. THESE LAWS INCLUDE, BUT ARE NOT LIMITED TO:
o Prohibition from directly or indirectly lobbying city personnel (Miami Beach City Code section 2-459).
o Prohibition from contracting with the city (Miami-Dade County Code section 2-11.1).
o Prohibition from lobbying before board/committee you have served on for period of one year after leaving office
(Miami Beach Code section 2-26)
o Requirement to disclose certain financial interests and gifts (Miami-Dade County Code section 2-11.1).
o Sunshine Law - Florida's Government-in-the-Sunshine Law was enacted in 1967. Today, the Sunshine Law
regarding open government can be found in Chapter 286 of the Florida Statutes. These statutes establish a basic
right of access to most meetings of Boards, Commissions, and other governing bodies of state and local
governmental agencies or authorities.
o Voting conflict - Form 8B is for use by any person serving at the county, city, or other local level of government on
an appointed or elected Board, Council, Commission, Authority, or Committee. It applies equality to members of
advisory and non-advisory bodies who are presented with a voting conflict of interest under Section 112.3143.
Florida Statutes.
o Commencing with terms beginning on or after January 1, 2024, and as a condition of applying for appointment to
a City agency, board, or committee, each applicant must voluntarily agree that in the event the applicant files with
the City Clerk a Statement of Candidate formally announcing candidacy for City elective office, such filing with the
City Clerk shall be deemed a tender of resignation from the City agency, board or committee, and the member's
automatic resignation shall thereby immediately create a vacancy in the agency, board, or committee.
● In what organization(s) in the City of Miami Beach do you currently hold membership in?
No Organization Information Submitted.
● List the address of all properties owned or in which you have an interest within the City of Miami Beach:
Property
1455 Ocean Drive, #1509, Miami Beach, FL 33139
If so, which department and title?No● Are you now employed by the City of Miami Beach:
● Pursuant to City Code Section 2-25 (b):
Do you have a parent, spouse, child, brother, or sister who is employed by the City of Miami Beach?No
If "Yes", identify person(s) and department(s):
No relative's information submitted.
BOARD & COMMITTEE FINANCIAL ACKNOWLEDGEMENT STATEMENT
Acknowledgement of fines/suspension for Board/Committee Members for failure to comply with
Miami-Dade County Financial Disclosure Code Section 2-11.1(i)(2)
I understand that no later than July 1, of each year all members of Boards and Committees of the City of Miami
Beach, including those of a purely advisory nature, are required to comply with Miami-Dade County Financial
Disclosure Requirements.
One of the following forms must be filled with the City Clerk of Miami Beach, 1700 Convention Center Drive,
Miami Beach, Florida, no later than 12:00 noon of July 1, of each year:
1. A "Source of Income Statement;" or
2. A "Statement of Financial Interests (Form 1)¹ ;" or
3. A Copy of your latest Federal Income Tax Return.
Failure to file one of these forms, pursuant to the Miami-Dade County Code, may subject the person to a fine of no
more than $500, 60 days in jail, or both.
_____________________________
¹ Members of the Planning Board and Board of Adjustment will be notified directly by the State of Florida, pursuant
to F.S. §112.3145(1)(a), to file a Statement of Financial Interests (Form 1) with the Miami-Dade County Supervisor of
Elections by 12:00 noon, July 1. Planning Board and Board of Adjustment members who file their Form 1 with the
County Supervisor of Elections automatically satisfy the County’s financial disclosure requirement as a Miami Beach
City Board/Committee member and need not file an additional form with the Office of the City Clerk. However,
compliance with the County disclosure requirement does not satisfy the State requirement.
DIVERSITY STATISTICS REPORT
The following information is voluntary and has no bearing on your consideration for appointment. It is being asked to
comply with City diversity reporting requirements.
WhiteRace/Ethnic Categories
What is your race?
No details providedOther Description:
Gender:Male
Are you Spanish/Hispanic/ Latino? Mark the "No" box if not Spanish / Hispanic /
Latino.
No
Physically Challenged:No
I HEREBY ATTEST TO THE ACCURACY AND TRUTHFULNESS OF THE APPLICATION; AND I HAVE
RECEIVED, READ AND WILL ABIDE BY CHAPTER 2, ARTICLE VII, OF THE MIAMI BEACH CITY CODE,
ENTITLED “STANDARDS OF CONDUCT FOR CITY OFFICERS, EMPLOYEES AND AGENCY MEMBERS AND
ALL OTHER APPLICABLE COUNTY AND/OR STATE LAWS AND STATUTES ACCORDINGLY.”
I Bruce Halpryn agreed to the following terms on 4/11/2024 4:40:32 PM
Received in the City Clerk's Office by:
Name of Deputy Clerk Control No. Date
Board and Committee Application Checklist: Please ensure you have provided all information before applying or
reapplying to any Board and Committee.
YES
YES
YES
YES
I have answered all questions fully.
I have uploaded a current resume, photograph, and a copy of any applicable professional license.
I have completed and attached the Board & Committee Financial Acknowledgment Statement.
I have completed and attached the Diversity Statistics Report.
If you have any questions, please contact the Office of the City Clerk via email: BC@miamibeachfl.gov or
telephone: 305.673.7411
Note: Florida Statutes 119.071: The role of the Office of the City Clerk is to receive and maintain forms filed as
public records. If your home address, telephone numbers, and/or photograph are exempt from disclosure and you
do not wish your home address, telephone numbers, and/or photograph to be made public, please:
1) Use your office or other address for your mailing address;
2) Use your office or other telephone number for your contact number; and
3) Do not attach a photograph.
YES I voluntarily agree to the resignation from the City agency, board, or committee, if I file a Statement
of Candidate for a City Elective Office (1).
(1) I understand that commencing with terms beginning on or after January 1, 2024, and as a condition of applying for
appointment to a City agency, board, or committee, I must voluntarily agree that in the event I file with the City Clerk a
Statement of Candidate formally announcing candidacy for City elective office, such filing with the City Clerk shall be deemed a
tender of resignation from the City agency, board, or committee.
Dr Bruce M. Halpryn
1455 Ocean Dr., #1509
Miami Beach, FL 33139
513-659-4690
-----EDUCATION-----
Ph.D. in biology, State University of New York at Binghamton. June 1983
B.S. in biology, State University of New York at Stony Brook. May 1979
-----CURRENT POSITIONS------
VISU Contemporary, LLC art gallery, -Majority owner, co-curator 6/23-present (Miami Beach, FL).
Developed a strategy to transform the gallery into a fine art gallery, bringing in A-Level artists to the
gallery to contrast to the multiple tourist art galleries already in the city.
Eikonoklastes Therapeutics, Co-founder, Chief Executive Officer and Board Chair, 6/2019-present
(Cincinnati, Ohio). Eikonoklastes Therapeutics is developing a pipeline of disruptive new therapies that it
can rapidly and relatively inexpensively move from preclinical stage to clinical proof-of-concept and
registration. We have now acquired our first two assets to treat devastating diseases that currently are
severely inadequately treated. Our focus is on novel compounds that: 1) have platform capability where one
molecule can treat multiple diseases with severe unmet clinical need, 2) will get preferred regulatory
treatment due to the high unmet need and breakthrough potential, and 3) need relatively small clinical trials
to achieve approval.
Our 1st in class gene therapy (ET-101) has been engineered to overexpress Caveolin-1, which organizes &
regulates synaptic receptors essential for neuromuscular signaling and function. It can treat a wide range of
neurodegenerative diseases through precise, targeted overexpression of Caveolin-1 in neurons .
Our first indications are neurodegenerative diseases with high unmet need and high mortality (e.g. ALS). A
robust pipeline of additional indications (e.g. Alzheimer’s, Parkinson’s, etc. for ET-101) with severely
inadequate treatment options will subsequently be pursued with these therapeutics.
Ohio I-CORPS Program, Adjunct Instructor, 6/2017-present (Columbus, Ohio). Instructor and mentor
for academic life science programs in the state of Ohio transitioning from an educational institution
environment to a bonafide commercial startup. Provide formal training in Business Model Generation and
Value Proposition Design and practical coaching on what it takes for Regulatory Agency approval and
Commercial Success.
Larta Institute, Senior Advisor, Life Sciences and Open Innovation, 2007-present (Los Angeles,
California). Larta’s mission is connecting people to drive innovation. Larta magages one of the the nation’s
largest innovation pipelines. They drive the success of technology companies by connecting them with the
right people, partners and capital. Their commercialization services help governments, universities and
corporations accelerate technology transfer and expedite its movement into commercialization. In that vein,
I am assigned as a confidential advisor by Larta to several promising start up companies each year, to help
them hone their pitch to investors, to advise them on their strategic approach to development and interaction
with regulatory agencies, to make appropriate introductions on their behalf to sources of capital and/or
potential partners or advisors to expedite their movement into commercialization. To date I have advised
companies with inventions in biotechnology, new drug candidates, diagnostics, and medical devices. With
help from some of my advice and connections, many of my start ups have reached fruition by either being
bought out, licensed or partnered by larger companies, or found Venture Capital and/or Angel funding to
continue development on their own. In December 2014, I was sought out by the government of Malaysia to
serve as Program Advisor to several of the inaugural companies in the Bioincubator they are establishing.
---- PREVIOUS EXPERIENCE-----
Myonexus Therapeutics, Inc. Co-Founder, Chief Operating Officer, and board Secretary 2/2017-
4/2019. Myonexus Therapeutics was a clinical stage gene therapy company developing first ever
treatments for Limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C. Led progression of
lead candidate from lab to first-in-human clinical studies and consequent acquisition by Sarepta (for total
consideration of up to $600M) in under 2 years. Clinical studies I designed and initiated showed
substantial expression of the missing critical protein in muscle cell biopsies of treated children, and
translation of that expression into significant and continuing improvement in muscle function at 9 months,
compared to a >5% decline in muscle function in historical controls over the same time period. This study
is still ongoing and is expected to show substantial restoration of muscle function approaching normal
healthy levels.
N8 Medical/Kinnear Pharmaceuticals, Chief Operating Officer, 2014-2016. N8 Medical is a preclinical-
stage pharmaceutical company developing innovative therapeutics based on a novel, proprietary class of
small molecule drug candidates known as ceragenins or Cationic Selective Antimicrobials. Current active
preclinical programs include: 1) an inhaled anti-infective for cystic fibrosis, 2) a next generation bone graft
substitute, 3) an oral mucositis therapeutic for head and neck cancer patients, 4) an inflammatory bowel
disease (“IBD”) therapeutic, and 5) a multiple myeloma therapeutic. After successful spinout of the medical
device coatings business, multiple programs were successfully brought to the IND stage; however, in Q1
2016, operations were suspended to divert precious resources to supporting IP infringement litigation.
Procter & Gamble Global One Health Sector, Sr. Director, Technology Development, Intellectual
Property Management, Open Innovation (Connect + Development), IP & Technical Due Diligence,
August 2009 to 2013. Technology responsibilities included leadership of the group responsible for the
innovation pipeline for our global OTC business including incremental product lifecycle innovations,
transformative products and disruptive new business opportunities amounting to >$100M of new business.
Several of these opportunities entered the market place in 2014 + 2015, with life cycle improvements
continuing to feed the market. Also led a team of patent agents and corporate patent attorneys in
management of the One Health Sector (Personal Health (OTC), Pet Care, Oral Care) patent portfolio and
provided IP strategy input into current portfolio, development projects, input into consideration of outside
opportunities and monitoring for infringement of our IP. Worked with Commercial, R&D, Product Supply,
Legal, IP, Tax, Finance, etc, led the open innovation “connect + develop” effort for global One Health Sector
including identifying, validating, and assessing outside opportunities and development of new tools and
procedures to increase the effectiveness and efficiency of these efforts. The processes developed have been
considered the “Gold Standard” in P&G and have been rolled out across the entire P&G company to every
business unit. Personally led all of the key IP & Technical Due Diligence reviews for the One Health Sector’s
outside opportunities as well as for our Future Works health care related opportunities. Trained others to
provide supplemental capability to lead due diligences as licensing increases. Served as internal corporate
consultant for IP & Technical Due Diligence efforts across all business units globally. Served as the
representative on the term sheet and contract negotiation teams for outside One Health opportunities validated
by due diligence as the representative looking our for all of the technical community’s (R&D, Product
Supply, etc) concerns. Additional responsibilities include: P&G chief technical liaison to Swiss Precission
Diagnostics our JV consumer diagnostics company; Secondee to Triathalon Ventures to oversee our VC
investment and identify appropriate opportunites for P&G to access, Managed the Due Diligence process that
enabled our JV with Teva Pharmaceuticals to reach closing.
Procter & Gamble Pharmaceuticals (formerly Norwich Eaton Pharmaceuticals), Director Connect &
Development/IP & Technical Due Diligence, 2005 – August 2009. When Pharmaceuticals decided to close
its internal research labs, I was asked to create a state of the industry Open Innovation Organization,
corresponding tools and best practices to build on the IP & Technical Due Diligence Capabilities I already
created. The capability created resulted in P&GP indentifying, validating, conducting due diligence and then
successfully negotiating and closing on 3-4 opportunities a year. Created tools to ensure all due diligences
were evaluated on a consistant basis so that various internal and external opportunities could have their risks
and potential evaluated and compared on a comparable basis. Personally led all of the key due diligences
and represented R&D on the contract negotiating teams. When P&G decided to divest pharmaceuticals, I
was asked to design and then lead the due diligence process for this divesture. The electronic data room was
the largest ever in Intralinks history before or since. Despite the enormity of the data base, the data was
organized in a fashion that there were few questions on where to find things. At one point I managed over
550 people with access to the electronic data room, all with different individual levels of clearance. I
managed all of the follow up technical discussions and questions. Pharmaceuticals was successfully divested
for $3.1B.
Procter & Gamble Pharmaceuticals, Director, Early Phase New Drug Development, 1995 to 2005.
Responsible for all Rx drug development projects in the portfolio from the pre-IND phase through proof-of-
concept and/or dose ranging, and co-responsible for the design of the phase III programs. This included
internally generated projects as well as acquisitions and partnerships. Responsible for development programs
in heart failure, osteoporosis, osteoarthritis, anti-angiogenesis, upper respiratory, hormone replacement,
diabetes and migraine. Responsible for the total strategic direction of these programs and matrixed
multidisciplinary teams (e.g., Clinical, Regulatory, Toxicology, Chemical Development, Dose Form
Development, Finance, etc.) with direct reporting responsibility to me for each of these programs. Complete
responsibility and authority (within an approved budget) for the direction of the programs. Responsible for
training future project leaders to assume responsibility for leading individual programs.
An additional major responsibility included personally leading the technical due-diligence “swat teams” on
all potential in-licensing and partnering opportunities and advising internal project teams on managing
technical due diligence for out licensing and partnering opportunities. This required creating procedures for
the conduct and communication of due diligences without “poisoning” internal personnel from being able to
pursue competitive approaches to the same target. Responsibilities were also expanded to do initial technical
evaluations of “non-focus area” opportunities that had been identified. After the acquisition of Groupo Vita
Pharmaceuticals in Barcelona, I had transitional responsibility for indoctrinating the R&D personnel into the
P&G policies, procedures and culture.
Procter & Gamble Pharmaceuticals, Associate Director Cardiac Drug Development/Project Leader
Heart Failure Development Program, 1995. Led team that prepared IND for second generation
inotrope/neurohumoral modulator. Supervise associate project leaders on other cardiac drug development
programs including arrhythmias, hypertension, cardioprotection/reperfusion injury. Had full responsibility
and authority for design and execution of cardiac programs within budget limitations. Responsibility covers
designing key animal studies to provide evidence that research lead has basis for marketplace superiority,
designing clinical program and product development support for clinical development program from IND to
NDA/PLA. Responsible for leading team to find partner for CHF development program. Lead technical and
market assessment of potential acquisitions and partnership opportunities for cardiac and non-cardiac drugs.
Additional responsibilities included design of clinical program and study protocols for upper respiratory
projects.
Procter & Gamble Pharmaceuticals, special assignment European Subsidiaries’ Regulatory Affairs,
1994-1995. Was sent to U.K. on special assignment to manage Regulatory Affairs organizations of P&GP’s
subsidiaries in Europe. Developed proposal, since implemented, for reporting relationships back into
European headquarters and into world-wide headquarters in Cincinnati as a result of new European
pharmaceutical legislation. Provided Regulatory Affairs input to strategy for expansion of pharmaceuticals
into white space markets in eastern Europe. Provided the regulatory support to allow initiation of
osteoporosis clinical trials in Russia. Created regulatory strategy for registration of ulcer “triple therapy” in
Europe.
Procter & Gamble Pharmaceuticals, special assignment Re-engineering of Pharmaceutical
organization for Time Based Competition, summer 1993. In a Boston Consulting Group facilitated re-
engineering of the pharmaceutical division to increase Time Based Competition, I was responsible for leading
the team that redefined the roles, responsibilities and reporting relationships of development project teams,
project leaders, core team members, functional managers and top management. Initial assessment, 1 year
later, has demonstrated an increased focus on project priorities as opposed to functional priorities. Key
measures of speed have improved 20-40% from baseline. Projects now have better defined strategies, and
have success criteria, and “go/no go” decision points built into the project plans.
Procter & Gamble Pharmaceuticals, Section Head Cardiac Drug Development. 11/90-6/93. Overall
leadership responsibility for international clinical development programs for heart failure. Led
multidisciplinary teams that prepared and filed 2 IND's and European equivalents in France, Germany, and
England. Extensive interaction with the regulatory agencies and key thought leaders has been a key aspect
of position's requirements. Led projects through end of phase II at which time compounds were discontinued.
Led the class III antiarrhythmic “backup” program through the research to development transition. Also
responsible for leading the "due diligence" review of regulatory and technical documents during acquisitions
of Minipress, Minipress XL, Ziac, and Zebeta. Acted as technical Brand Manager for these
marketed products until product was returned to Pfizer in case of Minipress or a replacement manager could
be trained in the case of Ziac/Zebeta.
Norwich Eaton Pharmaceuticals, Staff Scientist. 6/86-11/90. Established a new lab for the chronic
instrumentation and monitoring of hemodynamic variables in conscious dogs. Collaborated in development
of new models of heart failure for testing of new inotropic compounds. Directly supervised all in-vivo testing
of potential cardiotonic agents. Chief scientist responsible for pre clinical pharmacology on digitalis analogs
project. Project leader of digitalis analog progression team.
National Research Council at NASA/Ames Research Center, Research Fellow. 6/83-6/86. Managed
a research team investigating the cardiovascular de-conditioning effect seen as a result of the micro-gravity
environment during space flight and as a result of ground based simulations of low gravity. I also participated
in a study on the effect of chronic orthostatic and antiorthostatic hypokinesia on trabecular bone formation
in rhesus monkeys. I was co-investigator on the cardiovascular experiments flown aboard the U.S./U.S.S.R.
joint space flights; Cosmos 1514 and Cosmos 1667. I was responsible for the analysis and interpretation of
the cardiovascular flight data and ground based simulations. As part of this work I developed specialized
surgical and training techniques in order to conduct long-term chronic experimentation in non-human
primates. I was responsible for the implementation and physiological evaluation of a completely implantable
telemetry system that allows simultaneous monitoring of: multiple blood pressures; cardiac output;
temperature; and EKG in unrestrained animals.
NASA Graduate Student Training Grant, Pre-doctoral Fellowship. 12/79-6/83. I was responsible for
the development and implementation of long-term (two weeks) continuous (24 hours/day) monitoring
capabilities of cardiovascular variables. This monitoring capability enabled me to characterize the daily
changes that cardiovascular variables undergo, and to establish baseline values for heart rate, blood pressure,
cardiac output, stroke volume, and total peripheral resistance used by NASA as ground based controls for the
joint U.S. /U.S.S.R. Cosmos space flights. This work included conducting ground based controls establishing
pressure-flow relationships to the brain during control and space flight simulations. I created software for
the accurate micro-computer resolution of pulsatile physiological waveforms as well as specifying programs
for real time data acquisition and reduction on a mini-computer. I was responsible for the verification of new
instrumentation designed for the chronic measurement of carotid blood flow and pressure during space flight.
Tri-Tonics Corporation, physiological consultant. I designed studies to evaluate the safety of various
electronic animal training devices. I supervised the implementation of these safety studies as well as analyzed
and interpreted the results. Outcome of clinical studies to evaluate effectivenss and safety of anti-bark collars
proved pivotal for defending against animal cruelty litigation.
Suntext Corporation, independent contractor. I wrote the text and questions for the cardiovascular and
renal physiology sections of a computerized package to study for the medical boards.
Primate Products Incorporated, consultant. Helped in the design and implementation of a rhesus restraint
system used to fly monkeys aboard the Space Shuttle as part of the King Louis project. As part of this
project, I helped design a software package to control and record data from a psychomotor panel used for
behavioral enrichment while the monkey was in the restraint system.
Mission College, physiology instructor pool. Taught anatomy and physiology classes to community
college students on an as needed basis.
Palmer Station, Antarctica. I was part of a two man team investigating thermoregulation and
cardiovascular circadian rhythms in Adelie penguins. Through the use of various pharmacological nerve
blocks and varying environmental conditions, we elucidated the neural mechanisms of blood flow control to
the uninsulated flipper, foot and beak of the penguin. We also determined the relative importance of various
body sites in the penguins' thermoregulation. We were the first investigators to document a circadian rhythm
of body temperature in Antarctic penguins during the continuous light of the austral summer.
----COMMUNITY SERVICE----
Executive Board member, Miami City Ballet – Chair the School Committee, member of Finance
Committee, and member Personnel and Compensation Committee. Lead the creation of the first Strategic
Plan in the history of the ballet school. Played a key role in negotiating the new dorm project for the
Miami City Ballet School. Participated in the renewal of 10-year strategy for the Miami City Ballet.
Played a key role in the recruiting and evaluation of the new Executive Director of the Miami City Ballet.
Ex-President, Board of Trustees, current Treasurer of the Board FotoFocus – transformed the board from
predominantly a formality, to leading the creation of the organization’s Vision, Values, Mission and
Stragety. Fotofocus has now grown to the largest photography and lens-based art biannual in the country.
The organization is getting national and international attention for the quality of the curation of their shows
and the educational function they are providing about photography as an art form.
Ex-President, Board of Trustees, concert:nova – Ex-Chair of Governance and Marketing committees, lead
the process of creating the organizational Vision, Values, Mission and Strategy. The organization has
transformed from unstable startup arts organization to a stable, financially secure, recognized high value
contributor to the city arts community.
Ex-Board of Trustees, Cincinnati Ballet – previously chair of Artistic + Marketing committees. Passionate
about the dancers and the art form. Led numerous initiatives to support dancers such as a board mentorship
program for the dancers, dancer relations activities, dancer sponsorship program, etc. Sponsored the
building of the dancers’ lounge and locker rooms in the new Cincinnati Ballet headquarters.
Cincinnati Art Museum Shareholder, Co-Creator Friends of Photography affinity group – Support of
curator and mission to build a world class photography collection and educate the public of importance of
photography as an art form. Contributed to bringing in blue-chip photography exhibitions and new
photographs into the museum’s permanent collection.
-----HONORS AND AWARDS-----
NASA Certificate of Appreciation, 1986 (for contributions to the U.S./ U.S.S.R. Cosmos 1667 Spaceflight
Mission).
NASA Certificate of Appreciation, 1984 (for contributions to the U.S. / U.S.S.R. Cosmos 1514 Spaceflight
Mission).
National Research Council (NRC) Fellowship, 1983-1986.
NASA Graduate Student Training Grant, 1980-1983.
Congressional Antarctic Service Medal, 1982 (in recognition of contributions to scientific research in
Antarctica).
State University of New York research assistantship, 1979-1980.
Regents Scholar, State of New York, 1975-1979.
Board of Directors, Our Health Center - a non-profit community health clinic, 1982-1984.
Vice Chairman of the Board, concert:nova 2009-present
Board of Directors, Cincinnati Ballet 2011-present
-----PUBLICATIONS-----
Halpryn, Bruce M., E. Cabrera, V. Fulton, R. Fulton, T. Ogerau, S. Fenard, A. Baggioni, and Y. Chang .
LND 796, An Inotropic Steroid With Improved Separation Of Efficacy From Toxicity Compared To
Digoxin. Cardiovascular Drugs and Therapy (submitted)
Capasso, Joseph M., B. Halpryn, L.M. Quattrocci, G. Olivetti, P. Anversa). Response Of The
Hypertensive-Diabetic Rat Myocardium To 10 Weeks Of Oral Digoxin. American Journal of Physiology
(submitted)
Halpryn, Bruce M., R. Fulton, V. Fulton, T. Ogerau, S. Fenard, A. Baggioni, J. Koenig, Y. Chang . LND
796, A New, Safer Inotropic Steroid. The FASEB Journal (in-press)
Capasso, Joseph M., B. Halpryn, L.M. Quattrocci, G. Olivetti, P. Anversa (1988). Effects of Digoxin on
Global Cardiac Function of Hypertensive-Diabetic Rats. The Pharmacologist 30 (3): A41
Halpryn, Bruce M., R. Fulton, V. Fulton, R. Panasevich, T. Ogerau, S. Fenard, A. Bagioni, J. Koenig, Y.
Chang (1987). Activity of LND 623, a new inotropic steroid, in dogs. The Pharmacologist 29 (3): 135
Halpryn, Bruce M., R. Fulton, V. Fulton, R. Panasevich, T. Ogerau, S. Fenard, A. Baggioni, J. Koenig, Y.
Chang (1987). Activity of LND 623, a new inotropic steroid, in dogs. Proceedings of the Xth International
Congress of Pharmacology, Sydney.
Arnaud, Sara B., P. Patterson-Buckendahl, B.M. Halpryn, C. Maese, B.A. Harris, E. Morey-Holton, C.E.
Cann (1986). Endogenous Cortisol and serum osteocalcin in rhesus monkeys during simulated
weightlessness. Journal of Bone and Mineral Research 2 (suppl. I): 365.
Sandler, Harold V., Krotov, J., Hines, V., Magedov, B. Benjamin, A. Badakeva, B. Halpryn and H. Stone
(1985). Cardiovascular Results from a Rhesus Monkey Flow aboard the Cosmos 1514 Spacecraft. J. Avait
Space and Environ. Med.
Krotov, V., V. Magedov, H. Sandler, J. Hines, B. Benjamin. B. Halpryn, V. Krilov, N. MIlonov (1985).
Vosmoshmost registratziy ekstravasculyarmin arterialmovo davlana ee kravatok oo obezyan v
khronicheskom experimente (The possibliity of measuring pressure and flow extravascularly during
chronic experiments using monkeys). Bull. Exp. Biol. and Med. (in Russian).
Krotov, V., H. Sandler, A. Badakeva, J. Hines, A. Nazin, B. Halpryn (1985). Izucheniye terialnovo
davleniye uu skorosti krovotok oo obenzyaniy v kosmicheskom palyote (Changes in arterial pressure and
blood flow in a monkey during space flight). Proceedings of the All Union Conference on Aviation
Medicine June 1986, Kelyge, USSR.
Sandler, Harold, J. Hines, B. Halpryn (1985). Cosmos 1667 Cardiovascular Measurements - Experiment
Management Plan. NASA Technical Document.
Halpryn, Bruce M., E. Waterman, H. Sandler (1985). Effects of Various Restraint Chairs on Heart
Response in Rhesus Monkeys. The Physiologist 28 (4):365.
Halpryn, Bruce M. (1985). Biotelemetry Monitoring Systems. Laboratory Animal 14(6):21.
Halpryn, Bruce M., Paul Houghton (1984). The Pole and Collar Training Technique for Restraining
Rhesus Monkeys. NASA Technical Video.
Sandler, H., Lowell Stone, John W. Hines, Bruce Benjamin, Bruce Halpryn (1984). Preliminary Science
Report for Cosmos 1914 Primate Cardiovascular Experiment. NASA Technical Document.
Sandler, H., H. Lowell Stone, John W. Hines, Bruce Benjamin, Bruce Halpryn (1984). Preliminary
Science Report for Cosmos 1514 Primate Cardiovascular Experiment. NASA Technical Document.
Halpryn, Bruce M. (1983), Circadian Hemodynamics i the Rhesus Monkey: A Nervous Compensation to
Maintain Cerebral Blood Flow in the Upright Monkey at Night? Ph.D. Thesis.
Halpryn, Bruce M., David Murrish, Frank Sulzman, Harold Sandler (1983). Circadian Hemodynamics in
the Upright Sleeping Rhesus Monkey: A Sympathetic Nervous Compensation to maintain Cerebral Blood
Flow? The Physiologist 26(4):A76.
Halpryn, Bruce M., Paul Tirrell, Dave Murrish (1982). Circadian Rhythms in the Body Temperature of
Adelie Penguins. The Antarctic Journal of the United States 17(5):182
Halpryn, Bruce M., Dave Murrish, Frank Sulzman, Harold Sandler (1982). Cardiovascular Circadian
Rhythms in Rhesus Monkeys. The Physiologist 25(4): 189 Abst. 2.3.